Medicinal inorganic chemistry can exploit the unique properties of metal ions for the design of new drugs. This has, for instance, led to the clinical application of chemotherapeutic agents for cancer treatment, such as cisplatin. The use of cisplatin is, however, severely limited by its toxic side effects. This has spurred chemists to employ different strategies in the development of new metal-based anticancer agents with different mechanisms of action. Recent trends in the field are discussed in this review. These include the more selected delivery and/or activation of cisplatin-related prodrugs and the discovery of new non-covalent interactions with the classical target, DNA. The use of the metal as scaffold rather than reactive centre and the departure from the cisplatin paradigm of activity towards a more targeted, cancer cell-specific approach, a major trend, are discussed as well. All this, together with the observation that some of the new drugs are organometallic complexes, illustrates that exciting times lie ahead for those interested in 'metals in medicine'.
potential of metal-based anticancer agents has only been fully realised and explored since the landmark discovery of the biological activity of cisplatin [5] . To date, this prototypical anticancer drug remains one of the most effective chemotherapeutic agents in clinical use. It is particularly active against testicular cancer and, if tumours are discovered early, an impressive cure rate of nearly 100% is achieved. The clinical use of cisplatin against this and other malignancies is, however, severely limited by dose-limiting side-effects such as neuro-, hepato-and nephrotoxicity [5] . In addition to the high systemic toxicity, inherent or acquired resistance is a second problem often associated with platinum-based drugs, with further limits their clinical use. Much effort has been devoted to the development of new platinum drugs and the elucidation of cellular responses to them to alleviate these limitations [5, 6] . These problems have also prompted chemists to develop alternative strategies based on different metals and aimed at different targets. We summarize here recent activities in the field of metalbased anticancer drugs. Space limitations mean that this overview is not comprehensive, but aims to highlight significant advances and illustrate emerging trends.
New modes of interaction with the classical target, DNA
In classical chemotherapy, anticancer agents target DNA directly according to the cisplatin paradigm to generate lesions which ultimately trigger cell death. Much effort has been directed towards combatting the high systemic toxicity of traditional platinum anticancer agents by designing drug delivery systems capable of delivering platinum to tumour cells only.
A recent example of the latter strategy is the encapsulation of cisplatin and carboplatin in the hollow protein cage of the iron storage protein ferritin, which can be internalized by some tumour tissues. Indeed, the drug-loaded protein showed cytotoxic activity against the rat pheochromocytoma cell line (PC12) [7] . In a different approach, minicells, bacterially-derived 400 nm anucleate particles, have been packed with chemotherapeutics, such as cisplatin, and labelled with bispecific antibodies. This resulted in endocytosis and ultimately drug release in cancer cells [8] .
Platinum(IV) prodrugs can be used to overcome some of the problems associated with cisplatin and its analogues [9] . The high kinetic inertness of Pt(IV) complexes relative to their Pt(II) analogues introduces drug stability and the two extra ligands on the octahedral metal centre offer many possibilities for modification of pharmacokinetic parameters. As intracellular reduction of platinum(IV) to platinum(II) is usually essential for activation and subsequent cytotoxicity, these prodrugs essentially present better ways of delivering cisplatin (or its analogues) to the target tumour cell. 
Proteins and enzymes as non-classical targets
Traditional anticancer drugs that target DNA make use of the fact that malignant cells divide rapidly. A drawback of this strategy is that rapidly dividing healthy cells are affected as well, causing severe toxic side-effects. Alternatively, the design of novel agents that target cellular signalling pathways specific to cancer cells would therefore and 21 show pronounced cytotoxicity.
From inorganic to bioorganometallic drugs
The fact that many of the compounds mentioned above are organometallic complexes A dual strategy against platinum drug inactivation is presented by attaching a Pt(IV) prodrug to a carbon nanotube delivery system. The conjugate showed increased cellular uptake and displayed high cytotoxicity. The ability to attach other additional compounds to the platinated longboats provides an interesting opportunity for targeted delivery. 
